Skip to main content

Table 2 Immune-related adverse events

From: Safety and efficacy of anti-PD-1 in patients with baseline cardiac, renal, or hepatic dysfunction

irAE Grades 1/2 (N, %) Grades 3/4 (N, %)
Arthralgias 1 (4 %) 0
Colitis 0 1 (4 %)
Conjunctivis 1 (4 %) 0
Diarrhea 1 (4 %) 0
Hepatitis 0 2 (7 %)
Hypothyroidism 4 (15 %) 0
Nephritis 2 (7 %) 0
Pruritis 1 (4 %) 0
Rash 3 (11 %) 0
Vitiligo 1 (4 %) 0